Oruka Therapeutics Expands ORKA-001 License to Include Inflammatory Bowel Disease

summarizeSummary

Oruka Therapeutics has expanded its license agreement for ORKA-001 to include inflammatory bowel disease, opening a significant new market for its lead drug candidate, despite initial dosing restrictions.

check_boxKey Events

• License Agreement Amended

  On May 29, 2026, Oruka Therapeutics, Inc. entered into the First Amendment to its IL-23 License Agreement with Paragon Therapeutics, Inc.

• Expanded Therapeutic Field for ORKA-001

  The amendment expands the definition of 'Field' to encompass all therapeutic, prophylactic, palliative, and diagnostic uses, specifically including inflammatory bowel disease (IBD), which was previously excluded.

• Dosing Restrictions for IBD Trials

  Oruka is restricted from dosing human patients in clinical trials for IBD as a combination therapy until June 1, 2028, and as a monotherapy until June 1, 2030.

• Acceleration Clause for Restrictions

  Remaining restrictions outside the initial field will terminate on June 1, 2028, if Oruka or a Paragon licensee consummates a material transaction (e.g., change of control or sale of a lead candidate).

auto_awesomeAnalysis

Oruka Therapeutics has amended its IL-23 license agreement with Paragon Therapeutics, significantly expanding the potential market for its lead candidate, ORKA-001, to include inflammatory bowel disease (IBD). This strategic move opens up a large therapeutic area for future development, building on the recent positive Phase 2a data for ORKA-001. While there are restrictions on initiating IBD clinical trials until 2028 (combination) and 2030 (monotherapy), the long-term value proposition for ORKA-001 is substantially enhanced. The agreement also includes a clause that could accelerate these timelines if a material transaction occurs.